Adam S Zayac
Overview
Explore the profile of Adam S Zayac including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zayac A, Egini O, Palmisiano N, Evens A
Semin Perinatol
. 2025 Mar;
49(2):152041.
PMID: 40089320
Malignancies arising during pregnancy are an infrequent occurrence, leading to a paucity of data on the optimal management of cancers during pregnancy. Unlike most solid tumors, the primary, and often...
2.
Epperla N, Zayac A, Landsburg D, Bock A, Nowakowski G, Ayers E, et al.
Blood Adv
. 2024 Aug;
8(20):5355-5364.
PMID: 39189932
Little is known about the central nervous system (CNS) risk in high-grade B-cell lymphoma, not otherwise specified (HGBL NOS). Hence, we sought to describe the rates of baseline CNS involvement,...
3.
Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, et al.
Blood Adv
. 2023 May;
7(21):6381-6394.
PMID: 37171397
In this multi-institutional retrospective study, we examined the characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)-a rare category defined by high-grade morphologic features and...
4.
Ollila T, Masel R, Reagan J, Lu S, Rogers R, Paiva K, et al.
Cancer
. 2022 Jul;
128(18):3319-3329.
PMID: 35811461
Background: Patients with hematologic malignancies have impaired humoral immunity secondary to their malignancy and its treatment, placing them at risk of severe coronavirus disease-19 (COVID-19) infection and reduced response to...
5.
Wilson M, Eyre T, Kirkwood A, Doo N, Soussain C, Choquet S, et al.
Blood
. 2022 Jan;
139(16):2499-2511.
PMID: 34995350
Prophylactic high-dose methotrexate (HD-MTX) is often used for diffuse large B-cell lymphoma (DLBCL) patients at high risk of central nervous system (CNS) relapse, despite limited evidence demonstrating efficacy or the...
6.
Hsu A, Kurt H, Zayac A, Olszewski A
Leuk Lymphoma
. 2021 Sep;
63(1):31-42.
PMID: 34467833
We examined outcomes of 244 patients with marginal zone lymphoma (MZL) diagnosed in 2010-2020, of which 25 (10%) expressed CD5. CD5 expression was present in 22% of splenic, 8% of...
7.
Hsu A, Ohnigian S, Chang A, Liu Y, Zayac A, Olszewski A, et al.
R I Med J (2013)
. 2021 May;
104(5):14-19.
PMID: 34044431
COVID-19 infection has been associated with an increased incidence of thrombotic events leading to poor patient outcomes. Given the rapid rise of the COVID-19 pandemic, the ability to conduct prospective...
8.
Zayac A, Evens A, Danilov A, Smith S, Jagadeesh D, Leslie L, et al.
Haematologica
. 2021 Feb;
106(7):1932-1942.
PMID: 33538152
Central nervous system (CNS) involvement in Burkitt lymphoma (BL) poses a major therapeutic challenge, and the relative ability of contemporary regimens to treat CNS involvement remains uncertain. We described prognostic...
9.
Olszewski A, Jakobsen L, Collins G, Cwynarski K, Bachanova V, Blum K, et al.
J Clin Oncol
. 2021 Jan;
39(10):1129-1138.
PMID: 33502927
Purpose: Burkitt lymphoma (BL) has unique biology and clinical course but lacks a standardized prognostic model. We developed and validated a novel prognostic index specific for BL to aid risk...
10.
Hsu A, Zayac A, Eturi A, Almhanna K
Ann Transl Med
. 2020 Nov;
8(17):1109.
PMID: 33145328
Gastric and gastroesophageal junction (GEJ) cancer is one of the most common malignancy worldwide. In unresectable or metastatic disease, the prognosis is poor and is generally less than a year....